Dr. Claudia Padilla discusses Alzheimer’s and a new treatment.

Claudia Padilla, MD, at Baylor Scott & White Health, discusses Alzheimer’s and a new treatment. What You Need to Know: Alzheimer’s disease is a type of dementia. The most common sign is short-term memory loss. New medication targets the protein…

Can a Blood Test Detect Alzheimer’s Disease?

In July, the first direct-to-consumer blood test designed to assess a user’s risk for developing Alzheimer’s disease hit the market.

Small Percentage of People with Early Dementia Eligible for New Alzheimer’s Drugs

Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.

Cedars-Sinai Experts Discuss Pros, Cons of New Alzheimer’s Drug

Cedars-Sinai patient care teams are preparing to offer lecanemab, a new Alzheimer’s disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.

Annual Medicare spending could increase by $2 to $5 billion if Medicare expands coverage for dementia drug lecanemab

The anti-dementia medication lecanemab and its ancillary costs could add $2 billion to $5 billion in annual Medicare spending if the Centers for Medicare and Medicaid Services (CMS) revise their coverage decision. Currently, the medication is covered only for patients who are enrolled in clinical trials.

MEDIA ADVISORY: Cedars-Sinai Experts On Hand to Discuss New Alzheimer’s Drug Now Under Review

The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.